A practical reference on reconstitution: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-31 and is reviewed periodically as new material appears.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
=== Hotels === The Regent Palace Hotel, Glasshouse Street, London was operated by Strand Hotels Limited, a subsidiary of J. Lyons and Company and opened on 16 May 1915. Strand Hotels also operated the Cumberland Hotel (Marble Arch, London), Kingsley Hotel, Park Court Hotel, Windsor Hotel, White's Hotel and the Strand Palace Hotel after the inception of Strand Hotels Limited. The last London hotel that they operated until the demise of the group in the mid-1970s was the Tower Hotel situated by Tower Bridge in London.
== H == Hammock – The hammock was invented by indigenous peoples of the Caribbean and Central America. The word derives from the Taíno word hamaca. Christopher Columbus observed their use in the Bahamas in 1492. Harpoons – the Inuit had developed the harpoon independent of any Old World influences, in order to hunt seals, walrus, and whales. The Inuit of West Greenland called the harpoon maupok. Harpoons enabled the Inuit to hunt large marine mammals from a distance in the umiak and kayak in the open Arctic Ocean. Hockey – both field hockey and ice hockey are based on a game called shinny. This indigenous stickball game was played throughout North America well before the European arrival.
==== Dehydrogenases: equivalents to complexes I and II ==== Bacteria can use several different electron donors. When organic matter is the electron source, the donor may be NADH or succinate, in which case electrons enter the electron transport chain via NADH dehydrogenase (similar to Complex I in mitochondria) or succinate dehydrogenase (similar to Complex II). Other dehydrogenases may be used to process different energy sources: formate dehydrogenase, lactate dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase, H2 dehydrogenase (hydrogenase), electron transport chain. Some dehydrogenases are also proton pumps, while others funnel electrons into the quinone pool. Most dehydrogenases show induced expression in the bacterial cell in response to metabolic needs triggered by the environment in which the cells grow. In the case of lactate dehydrogenase in E. coli, the enzyme is used aerobically and in combination with other dehydrogenases. It is inducible and is expressed when the concentration of DL-lactate in the cell is high.
Sources: en.wikipedia.org
M791 armor-piercing discarding sabot with tracer The APDS-T penetrates lightly armored vehicles, self-propelled artillery, and aerial targets such as helicopters and various slow-moving, fixed-wing aircraft. Reported velocity of 1,345 m/sec. M792 high explosive incendiary with tracer and self destruct The HEI-T can destroy unarmored vehicles and helicopters and suppress anti-tank missile positions and enemy squads out to a maximum effective range of 2,200 meters. Uses the M758 fuse, reported velocity of 1,100 m/sec. M793 target practice with tracer The TP-T cartridge is a fixed-type, percussion-primed training round that matches the high explosive incendiary with tracer (HEI-T M792) round ballistically. The TP-T's tracer is visible out to 2,000 meters, however, the round has a maximum effective range (accuracy-limited) of 1,600 meters. Reported velocity of 1,100 m/sec. M910 target practice discarding sabot with tracer The TPDS-T replicates the flight pattern of the M791 armor piercing discarding sabot with tracer (APDS-T) round. The TPDS-T allows units to realistically practice sabot engagements. Reported velocity of 1,515 m/sec. MK210 high explosive incendiary with tracer Used by the U.S. Navy in their Mk38 naval weapon system. M919 armor-piercing, fin-stabilized discarding sabot with tracer. The APFSDS-T round penetrates lightly armored vehicles, self-propelled artillery, and aerial targets, which include helicopters and slow-moving fixed-wing aircraft. The dart is made of depleted uranium.
Colombia has more than 3,950 research groups in science and technology. iNNpulsa, a government body that promotes entrepreneurship and innovation in the country, provides grants to startups, in addition to other services it and institutions provide. Colombia was ranked 71st in the Global Innovation Index in 2025. Co-working spaces have arisen to serve as communities for startups large and small. Organizations such as the Corporation for Biological Research (CIB) for the support of young people interested in scientific work has been successfully developed in Colombia. The International Center for Tropical Agriculture based in Colombia investigates the increasing challenge of global warming and food security. Important inventions related to medicine have been made in Colombia, such as the first external artificial pacemaker with internal electrodes, invented by the electrical engineer Jorge Reynolds Pombo, an invention of great importance for those who suffer from heart failure. Also invented in Colombia were the microkeratome and keratomileusis technique, which form the fundamental basis of what now is known as LASIK (one of the most important techniques for the correction of refractive errors of vision) and the Hakim valve for the treatment of hydrocephalus. Colombia has begun to innovate in military technology for its army and other armies of the world; especially in the design and creation of personal ballistic protection products, military hardware, military robots, bombs, simulators and radar. Some leading Colombian scientists are Joseph M.
== Awards and honours == 2007 Donald F. Steiner Award for Outstanding Diabetes Research, University of Chicago 2008 Prix Galien Canada for Outstanding Pharmaceutical Research 2009 Clinical Investigator Award, Endocrine Society 2012 Claude Bernard Prize, European Association for the Study of Diabetes 2012 Fellow of the Royal Society of Canada 2013 Oon International Award for Preventative Medicine, University of Cambridge 2014 Banting Medal for Scientific Achievement, American Diabetes Association 2014 Manpei Suzuki Foundation International Prize for Diabetes, Japan 2015 Fellow of the Royal Society 2015 Officer of the Order of Canada 2017 Rolf Luft Award in Endocrinology and Diabetes Research, Karolinska Institute 2017 Harrington Prize for Innovation in Medicine, American Society for Clinical Investigation and the Harrington Institute (co-recipient with Joel Habener and Jens Juul Holst) 2019 Harold Hamm International Prize for Biomedical Research in Diabetes 2019 Novo Nordisk Foundation and European Association for the Study of Diabetes Prize for Excellence in Diabetes Research (watch the mini documentary about Drucker produced by the Novo Nordisk Foundation for the occasion) 2019 Lifetime Achievement Award, Helmholtz Diabetes Centre, Germany 2020 John Baxter Award for Entrepreneurship, Endocrine Society 2020 Transatlantic Medal, Society for Endocrinology 2020 Warren Alpert Foundation Prize for Biomedical Research (co-recipient with Joel Habener and Jens Juul Holst) 2021 International Member, National Academy of Sciences 2021 Canada Gairdner International Award (co-recipient with Joel Habener and Jens Juul Holst) 2022 Inductee of the Canadian Medical Hall of Fame 2023 Wolf Prize in Medicine 2023 International Member of the National Academy of Medicine 2023 VinFuture Prize for Innovators with Outstanding Achievements in Emerging Fields (co-recipient with Joel Habener, Jens Juul Holst and Svetlana Mojsov) 2024 Princess of Asturias Award for Technical and Scientific Research (co-recipient with Jeffrey M. Friedman, Joel Habener, Jens Juul Holst and Svetlana Mojsov) 2024 Time100 Most Influential People and Time100 Health 2024 Golden Plate Award, American Academy of Achievement 2024 Fred Conrad Koch Lifetime Achievement Award, Endocrine Society 2024 TOPS Research Achievement Award, The Obesity Society 2025 Warren Triennial Prize, Massachusetts General Hospital (co-recipient with Joel Habener and Svetlana Mojsov) 2025 BBVA Foundation Frontiers of Knowledge Award in Biology and Biomedicine (co-recipient with Joel Habener, Jens Juul Holst and Svetlana Mojsov) 2025 Solomon A. Berson Award, American Physiology Society 2025 Breakthrough Prize in Life Sciences (co-recipient with Joel Habener, Jens Juul Holst, Svetlana Mojsov and Lotte Bjerre Knudsen) 2026 Governor General's Innovation Award
Sources: en.wikipedia.org
Yellow biotechnology refers to the use of biotechnology in food production (food industry), for example in making wine (winemaking), cheese (cheesemaking), and beer (brewing) by fermentation. It has also been used to refer to biotechnology applied to insects. This includes biotechnology-based approaches for the control of harmful insects, the characterisation and utilisation of active ingredients or genes of insects for research, or application in agriculture and medicine and various other approaches. Gray biotechnology is dedicated to environmental applications, and focused on the maintenance of biodiversity and the remotion of pollutants. Brown biotechnology is related to the management of arid lands and deserts. One application is the creation of enhanced seeds that resist extreme environmental conditions of arid regions, which is related to the innovation, creation of agriculture techniques and management of resources. Violet biotechnology is related to law, ethical and philosophical issues around biotechnology. Microbial biotechnology has been proposed for the rapidly emerging area of biotechnology applications in space and microgravity (space bioeconomy) Dark biotechnology is the color associated with bioterrorism or biological weapons and biowarfare which uses microorganisms, and toxins to cause diseases and death in humans, livestock and crops.
== Therapeutic potential == In a test of pharmacologic asprosin depletion in animals, preliminary results raised the possibility of its use, therapeutically, in treating type 2 diabetes and obesity. For instance, Chopra and coworkers observed that when monoclonal antibodies targeting asprosin were injected into diabetic mice, blood glucose and insulin levels improved.
Politicians are usually targeted for three reasons: (1) Political figures who are honest pose a direct threat to organized crime, and are consequently killed by cartels; (2) Politicians make arrangements to protect a certain cartel and are killed by a rival cartel; and (3) A cartel kills politicians to heat the turf of the rival cartel that operates in the area.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.